Search Results - Cade, Jerry
- Showing 1 - 3 results of 3
-
1
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus by Thompson, Melanie, Saag, Michael, DeJesus, Edwin, Gathe, Joseph, Lalezari, Jay, Landay, Alan L., Cade, Jerry, Enejosa, Jeffrey, Lefebvre, Eric, Feinberg, Judith
Published 2016Text -
2
116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results... by Mills, Anthony, Richmond, Gary J, Newman, Cheryl, Osiyemi, Olayemi, Cade, Jerry, Brinson, Cynthia, De Vente, Jerome, Andany, Nisha, Margolis, David, Sutton, Kenneth, Wilches, Viviana, Roberts, Jeremy, McCoig, Cynthia C, Vandermeulen, Kati, Spreen, William
Published 2020Text -
3
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy by Mills, Anthony, Richmond, Gary J., Newman, Cheryl, Osiyemi, Olayemi, Cade, Jerry, Brinson, Cynthia, De Vente, Jerome, Margolis, David A., Sutton, Kenneth C., Wilches, Viviana, Hatch, Sarah, Roberts, Jeremy, McCoig, Cynthia, Garris, Cindy, Vandermeulen, Kati, Spreen, William R.
Published 2022Text